Healthtech Exec Committed to Patient-First Innovation | Ro Employee #3 | Startup Leader | Strategic Advisor | Builder of High-Performing Teams
Blue Health Intelligence released a brief looking at factors predicting GLP-1 agonist treatment persistence. This particular brief only includes Saxenda (liraglutide 3.0 mg daily) and Wegovy (semaglutide 1.7mg or 2.4mg weekly). I share the most important highlights below. • > 50% of people prescribed one of these drugs for obesity stopped taking it in less than 12 weeks, which would not be enough time to see benefit • People were more likely to continue treatment beyond 12 weeks if the drug was prescribed by an obesity physician or endocrinologist—this might be due to these clinicians being better at coaching patients through the early period when side effects are most common • Patients < 35 years old were less likely to continue treatment past 12 weeks • Patients with the most social vulnerability were the least likely to continue treatment past 12 weeks • Those with more frequent healthcare visits were more likely to continue treatment past 12 weeks This is a health insurance study, not a scientific study. Nonetheless, it suggests that coaching and guidance from medical providers is an important factor in continuing these medications. Link in comments. #obesitymedicine #semaglutide #wegovy #liraglutide #saxenda #obesity
Healthtech Exec Committed to Patient-First Innovation | Ro Employee #3 | Startup Leader | Strategic Advisor | Builder of High-Performing Teams
10mohttps://www.bcbs.com/sites/default/files/BHI_Issue_Brief_GLP1_Trends.pdf